Skip to main content

Table 2 Favorability ratings of immunomodulatory therapies

From: Corticosteroid-sparing therapy: practice patterns among uveitis specialists

  MTX MMF AZA CSA CTX INF ADA
Favorablea
Anterior 28 (62%) 24 (53%) 13 (29%) 9 (20%) 21 (47%) 37 (82%) 33 (73%)
Intermediate 20 (44%) 27 (60%) 14 (31%) 17 (38%) 24 (53%) 31 (69%) 26 (58%)
Posterior/panuveitis 10 (22%) 24 (53%) 15 (33%) 20 (44%) 32 (71%) 32 (71%) 25 (56%)
No opinion
Anterior 0 (0%) 7 (16%) 19 (42%) 16 (36%) 20 (44%) 5 (11%) 10 (22%)
Intermediate 1 (2%) 4 (9%) 13 (29%) 11 (24%) 17 (38%) 7 (16%) 12 (27%)
Posterior/panuveitis 1 (2%) 2 (4%) 11 (24%) 7 (16%) 9 (20%) 7 (16%) 16 (36%)
  1. MTX methotrexate, MMF mycophenolate mofetil, AZA azathioprine, CSA cyclosporine, CTX cyclophosphamide, INF infliximab, ADA adalimumab
  2. aRating question responses of “mostly effective” or “very effective” were considered favorable. Respondents could also indicate if they had no opinion for a particular combination